Want to see MRK full AI Analyst Report?
MRK Stock Chart & Stats
$131.07
$0.59(0.45%)
At close: 4:00 PM EDT
$131.07
$0.59(0.45%)
Day’s Range― - ―
52-Week Range$77.58 - $154.49
Previous CloseN/A
Volume6.15M
Average Volume (3M)10.42M
Market Cap
$367.58B
Enterprise Value$364.17K
Total Cash (Recent Filing)$7.14B
Total Debt (Recent Filing)$53.91B
Price to Earnings (P/E)121.1
Beta0.23
Next Earnings
Oct 29, 2026EPS Estimate
2.22Next Dividend Ex-DateN/A
Dividend Yield2.2%
Share Statistics
EPS (TTM)1.26
Shares Outstanding2,467,171,600
10 Day Avg. Volume8,822,586
30 Day Avg. Volume10,418,009
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)5.01
Price to Sales (P/S)4.06
P/FCF Ratio21.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$150.20Price Target Upside14.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)2.75
Revenue Forecast (FY)$67.13B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationRobust and improving free cash flow supports dividends, repurchases and debt service. This gives Merck internal funding capacity for research, launches and business development while reducing reliance on external capital.
Pipeline And Product ExpansionA broad pipeline with regulatory progress and positive late-stage data can diversify future revenue beyond established products. New launches and indications also improve the company’s ability to sustain growth as older therapies mature.
Diversified Healthcare PortfolioMerck combines oncology, vaccines, infectious disease, respiratory medicines and Animal Health. This breadth reduces dependence on any single therapeutic area and provides multiple channels for durable product adoption and geographic expansion.
Bears Say
Higher LeverageRising leverage reduces financial flexibility and increases the resources required for interest and debt service. If profitability remains pressured, higher debt could constrain acquisitions, shareholder returns and investment in the pipeline.
Weaker ProfitabilityThe sharp TTM decline in earnings and margins makes results less predictable and weakens returns on the company’s substantial capital base. Lower profitability can limit reinvestment capacity even though gross margins remain healthy.
Keytruda Concentration And Maturing GrowthKEYTRUDA remains a major revenue contributor, so moderating U.S. growth increases pressure on newer products and pipeline candidates to offset maturation. This concentration can make medium-term revenue growth more dependent on successful launches.
Merck & Company News
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $77.58 and its highest was $154.49 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $367.58B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Oct 29, 2026 which is in 67 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Aug 04, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.14.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.85 which represents an annual dividend yield of 2.2%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.22.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,467,171,600 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went up 0.18%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in MRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$150.20 (14.60% Upside)
$150.20 (14.60% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 85%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 11.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $30.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Very Bullish
Bullish news 98%
Bearish news 2%
Bearish news 2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.52%
12-Months-Change
Fundamentals
Return on Equity
2.20%
Trailing 12-Months
Asset Growth
10.45%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
MRK Company Deck
MRK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and scientific story: core revenue growth (Q2 +5%), several strong product performances (KEYTRUDA, WELIREG, WINREVAIR), meaningful vaccine and pneumococcal momentum, multiple important regulatory approvals and positive Phase III readouts (LIPFENDRA approval, sac-TMT, tulisokibart induction, islatravir combos), and raised/narrowed revenue guidance. Offsetting these positives are material one-time charges from the Terns acquisition that produced a GAAP loss and drove a volatile tax rate, margin and expense pressure, one clinical setback (SSc-ILD), and some near-term commercial headwinds (OHTUVAYRE unwind, moderating KEYTRUDA U.S. growth). Overall, management emphasized pipeline derisking, continued launches, and long-term opportunity, while acknowledging short-term impacts from the acquisition and inventory/reserve dynamics.View all MRK earnings summariesMRK Sales Breakdown
89.43% Pharmaceutical
9.77% Animal Health
0.79% Other
MRK Stock 12 Month Forecast
Average Price Target
$150.20
▲(14.60% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
21.80% Mutual Funds
14.31% Other Institutional Investors
38.67% Public Companies and Individual Investors